title: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
abstract: OBJECTIVE
  The long-term survival of patients with peritoneal carcinomatosis of colorectal origin has been achieved with cytoreductive surgery, which removes all macroscopic implants, combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The current technology for administering intraperitoneal heated chemotherapy is expensive and, for some institutions, unaffordable. We conducted this study to assess the temperature stability provided by a modified, inexpensive system, to offer a simple and low cost alternative to the standard HIPEC delivery equipment.
  
  
  METHODS
  Ten patients with histologically diagnosed peritoneal metastases of adenocarcinoma or pseudomyxoma peritonei underwent cytoreductive surgery and received HIPEC with 5-fluorouracil for 90 min, delivered via our modified system. The temperature was recorded from two probes: one in the inflow catheter and one in the outflow catheter. The intra-abdominal temperature was monitored meticulously to maintain it at between 41 and 42 °C.
  
  
  RESULTS
  All patients underwent cytoreductive surgery and HIPEC using our modified delivery system. Temperature stability was achieved in all patients, with a mean of 41.4°. There were no thermal injuries associated with any of the ten perfusions. The mean hospital stay was 15 days and the median survival was 30 months.
  
  
  CONCLUSIONS
  Analysis of this data demonstrates that the uniform delivery of HIPEC at 41° with this modified system is feasible and safe. The outcome of the patients treated with cytoreductive surgery and HIPEC with this modified system compares favorably to other published series. Its low cost and simple design will give more patients with peritoneal carcinomatosis access to this treatment.
authors.affiliation: Hospital de Oncologia, Department of Surgical Oncology, Colorectal service, Hospital de Oncologia Centro Medico Nacional "Siglo XXI" IMSS, Mexico City, Mexico. adriancravioto@mac.com.
authors.forename: Adrian
authors.initials: A
authors.lastname: Cravioto-Villanueva
authors.affiliation: Hospital de Oncologia, Department of Surgical Oncology, Colorectal service, Hospital de Oncologia Centro Medico Nacional "Siglo XXI" IMSS, Mexico City, Mexico.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Cavazos
authors.affiliation: Hospital de Oncologia, Department of Surgical Oncology, Colorectal service, Hospital de Oncologia Centro Medico Nacional "Siglo XXI" IMSS, Mexico City, Mexico.
authors.forename: Pedro
authors.initials: P
authors.lastname: Luna-Perez
authors.affiliation: Hospital de Oncologia, Department of Surgical Oncology, Colorectal service, Hospital de Oncologia Centro Medico Nacional "Siglo XXI" IMSS, Mexico City, Mexico.
authors.forename: Hector
authors.initials: H
authors.lastname: Martinez-Gomez
authors.affiliation: Hospital de Oncologia, Department of Surgical Oncology, Colorectal service, Hospital de Oncologia Centro Medico Nacional "Siglo XXI" IMSS, Mexico City, Mexico.
authors.forename: María Lourdes
authors.initials: ML
authors.lastname: Ramirez
authors.affiliation: Hospital de Oncologia, Department of Surgical Oncology, Colorectal service, Hospital de Oncologia Centro Medico Nacional "Siglo XXI" IMSS, Mexico City, Mexico.|Department of Cardiovascular Surgery, Perfusion Medicine, Centro Medico Nacional "Siglo XXI" IMSS, Hospital de Cardiologia, Mexico City, Mexico.|Peritoneal Surface Malignancy Program, GI Surgical Oncology, St. Agnes Health Care, Baltimore, MD, USA.
authors.forename: Juan
authors.initials: J
authors.lastname: Solorzano
authors.affiliation: Department of Cardiovascular Surgery, Perfusion Medicine, Centro Medico Nacional "Siglo XXI" IMSS, Hospital de Cardiologia, Mexico City, Mexico.
authors.forename: Hermelindo
authors.initials: H
authors.lastname: Montiel
authors.affiliation: Peritoneal Surface Malignancy Program, GI Surgical Oncology, St. Agnes Health Care, Baltimore, MD, USA.
authors.forename: Jesus
authors.initials: J
authors.lastname: Esquivel
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures / Q000379:methods*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral / Q000379:methods; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D011553:Pseudomyxoma Peritonei / Q000188:drug therapy / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005472:Fluorouracil
keywords: Cytoreduction; Intraperitoneal hyperthermic chemotherapy; Peritoneal carcinomatosis; Peritonectomy; colorectal cancer